Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. is poised for significant future growth, supported by a projected improvement in its legacy Performance Suite Medical Expense Ratio (MER) by 500 basis points, reaching 89%. The company's robust growth strategy includes cross-selling new services and upselling risk-based products, coupled with the expectation of strong top-line growth through increased contract acquisitions and improved margins, targeting a $150 million EBITDA run-rate by the end of 2026. Furthermore, the anticipated sequential EBITDA increases in the upcoming quarters, amounting to $32.5 million in Q3 and $45 million in Q4, underscore the company's strong operational performance and optimism for continued financial success.

Bears say

Evolent Health Inc. is experiencing significant challenges, as evidenced by a projected revenue decline of approximately $100 million related to its legacy Performance Suite, leading to anticipated revenues of around $850 million for that segment. Furthermore, the company has lowered its earnings per share (EPS) estimates for 2026 and 2027 to $0.18 and $0.45, respectively, from previous estimates of $0.34 and $0.52, indicating worsening financial prospects. Additionally, although the company expects some cost reductions from efficiency initiatives, the overall outlook remains bleak, with flat sequential performance anticipated for the second quarter and ongoing declines in critical revenue streams.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.